Cardiff Oncology, Inc. (NASDAQ:CRDF) Shares Sold by Two Sigma Investments LP

Two Sigma Investments LP lowered its position in Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) by 43.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 105,227 shares of the company's stock after selling 79,346 shares during the period. Two Sigma Investments LP owned about 0.21% of Cardiff Oncology worth $457,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its holdings in Cardiff Oncology by 68.7% during the fourth quarter. Bank of New York Mellon Corp now owns 288,615 shares of the company's stock worth $1,253,000 after acquiring an additional 117,514 shares during the period. Nuveen Asset Management LLC boosted its position in shares of Cardiff Oncology by 73.7% during the 4th quarter. Nuveen Asset Management LLC now owns 586,616 shares of the company's stock worth $2,546,000 after purchasing an additional 248,850 shares in the last quarter. Laurion Capital Management LP purchased a new position in shares of Cardiff Oncology in the 4th quarter valued at about $2,504,000. American Century Companies Inc. lifted its stake in shares of Cardiff Oncology by 12.8% in the fourth quarter. American Century Companies Inc. now owns 53,955 shares of the company's stock valued at $234,000 after purchasing an additional 6,140 shares during the period. Finally, Northern Trust Corp boosted its holdings in Cardiff Oncology by 8.9% during the fourth quarter. Northern Trust Corp now owns 337,092 shares of the company's stock worth $1,463,000 after buying an additional 27,489 shares in the last quarter. Institutional investors and hedge funds own 16.29% of the company's stock.

Cardiff Oncology Trading Up 0.5%

Shares of NASDAQ:CRDF traded up $0.02 on Friday, hitting $3.81. The company had a trading volume of 997,355 shares, compared to its average volume of 1,168,054. The company has a market cap of $253.46 million, a PE ratio of -4.05 and a beta of 1.61. Cardiff Oncology, Inc. has a 52-week low of $2.01 and a 52-week high of $5.64. The business has a 50 day moving average of $2.99 and a 200 day moving average of $3.51.

Cardiff Oncology (NASDAQ:CRDF - Get Free Report) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The firm had revenue of $0.11 million for the quarter, compared to analyst estimates of $0.09 million. Cardiff Oncology had a negative return on equity of 73.97% and a negative net margin of 6,238.17%. As a group, equities analysts predict that Cardiff Oncology, Inc. will post -0.99 EPS for the current year.

Analyst Ratings Changes

Separately, HC Wainwright increased their price target on shares of Cardiff Oncology from $17.00 to $18.00 and gave the company a "buy" rating in a research report on Friday, May 9th.

Cardiff Oncology Company Profile

Cardiff Oncology, Inc, a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.